CSPC Pharmaceutical Group Limited ‘s clinical trial for the recombinant fully human anti-ACTRIIA/IIB monoclonal antibody has been approved
November 27, 2025
Source: drugdu
51
Beijing Business News (Reporter Wang Yinhao, Song Yuying) - On November 26th, Shigao Group announced that the recombinant fully human anti-ActRIIA/IIB monoclonal antibody drug (JMT206) developed by the group has been approved by the National Medical Products Administration and can conduct clinical trials in China.
The announcement shows that this product can specifically bind to both activin receptor type IIA and type IIB simultaneously, blocking the binding of activin A, myostatin, and growth differentiation factor 11 to activin receptor type II, thereby inhibiting the activation of downstream signaling pathways, reducing muscle loss, and promoting the maintenance and growth of skeletal muscles, achieving the effect of muscle gain and fat loss. At the same time, this product can also assist GLP-1 receptor agonists in achieving higher-quality weight loss efficacy. The approved clinical indication for this approval is weight management for obese or overweight individuals with at least one weight-related comorbidity.
https://finance.eastmoney.com/a/202511263575661579.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
